Brussels Practice
Overview
Crowell’s office in Brussels has provided local and multinational clients with the full complement of legal services both in Belgium and Europe as a whole. Dispute resolution is at the core of our practice, and our renowned litigators represent clients before all the Belgian courts as well as before the Court of Justice of the European Union.
Our Brussels office has a strong tradition of serving the local community. Through our pro bono work, we assist and represent those who desperately need help in matters such as immigration, civil law, and domestic violence. For example, several of our lawyers offer their services to the “Legal Helpdesk,” a Brussels Bar initiative, and we also periodically set up a firm weekend “Call-in Clinic,” which offers free first line legal advice.
Insights
Client Alert | 2 min read | 03.12.26
The EU Pharma Package: Formal Adoption in Sight
The EU Pharma Package represents the most significant reform of EU pharmaceutical legislation in over two decades, setting the stage for a new era in medicine regulation. Introduced by the European Commission back in April 2023, the proposals are designed to promote innovation, strengthen medicine availability and affordability, reduce regulatory burdens, ensure a fair and competitive European pharmaceutical market, and modernize the EU's pharmaceutical framework. The EU Pharma Package will replace the more than twenty-year-old Directive 2001/83/EC and Regulation 726/2004, and incorporates the separate regulations on orphan and pediatric medicines, thereby bringing the entire regulatory framework up to date.
Client Alert | 4 min read | 03.11.26
CJEU Sets the Bar Low for Evidence Disclosure in Competition Damages Litigation
Client Alert | 5 min read | 02.18.26
The CeramTec Case, or How to (not) Navigate the Patent to Trademark Transition
Webinar | 11.24.25
AI in the Workplace: EU Rules for When Humans and Bots Team Up
Insights
Sowieso sexy: queer stereotypen in generatieve artificiële intelligentie
|01.27.25
Auteurs & Media, n°3, p. 326-331
A Christmas gift for the biosimilar industry: Landmark judgment in SPC Manufacturing Waiver case
|12.31.24
Kluwer Patent Blog
Speakers:
Academy of European Law's Summer Course on European Information Technology Law
|09.19.22 - 09.23.22
Professionals
Partner
Insights
Client Alert | 2 min read | 03.12.26
The EU Pharma Package: Formal Adoption in Sight
The EU Pharma Package represents the most significant reform of EU pharmaceutical legislation in over two decades, setting the stage for a new era in medicine regulation. Introduced by the European Commission back in April 2023, the proposals are designed to promote innovation, strengthen medicine availability and affordability, reduce regulatory burdens, ensure a fair and competitive European pharmaceutical market, and modernize the EU's pharmaceutical framework. The EU Pharma Package will replace the more than twenty-year-old Directive 2001/83/EC and Regulation 726/2004, and incorporates the separate regulations on orphan and pediatric medicines, thereby bringing the entire regulatory framework up to date.
Client Alert | 4 min read | 03.11.26
CJEU Sets the Bar Low for Evidence Disclosure in Competition Damages Litigation
Client Alert | 5 min read | 02.18.26
The CeramTec Case, or How to (not) Navigate the Patent to Trademark Transition
Webinar | 11.24.25
AI in the Workplace: EU Rules for When Humans and Bots Team Up
Practices
- Antitrust and Competition — Brussels Practice
- Corporate and Commercial — Brussels Practice
- Sustainability and Environmental, Social, and Governance (ESG)
- Dispute Resolution — Brussels Practice
- Intellectual Property — Brussels Practice
- International Trade — Brussels Practice
- International Dispute Resolution — Brussels Practice
- Labor and Employment — Brussels Practice
- Privacy and Cybersecurity — Brussels Practice
- Regulatory — Brussels Practice
- Technology, Media, and Telecommunications — Brussels Practice
- Public & Administrative Law — Brussels Practice
Insights
Client Alert | 2 min read | 03.12.26
The EU Pharma Package: Formal Adoption in Sight
The EU Pharma Package represents the most significant reform of EU pharmaceutical legislation in over two decades, setting the stage for a new era in medicine regulation. Introduced by the European Commission back in April 2023, the proposals are designed to promote innovation, strengthen medicine availability and affordability, reduce regulatory burdens, ensure a fair and competitive European pharmaceutical market, and modernize the EU's pharmaceutical framework. The EU Pharma Package will replace the more than twenty-year-old Directive 2001/83/EC and Regulation 726/2004, and incorporates the separate regulations on orphan and pediatric medicines, thereby bringing the entire regulatory framework up to date.
Client Alert | 4 min read | 03.11.26
CJEU Sets the Bar Low for Evidence Disclosure in Competition Damages Litigation
Client Alert | 5 min read | 02.18.26
The CeramTec Case, or How to (not) Navigate the Patent to Trademark Transition
Webinar | 11.24.25
AI in the Workplace: EU Rules for When Humans and Bots Team Up
